GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohit Oyj (OHEL:BIOBV) » Definitions » COGS-to-Revenue

Biohit Oyj (OHEL:BIOBV) COGS-to-Revenue : 0.42 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Biohit Oyj COGS-to-Revenue?

Biohit Oyj's Cost of Goods Sold for the six months ended in Dec. 2023 was €2.79 Mil. Its Revenue for the six months ended in Dec. 2023 was €6.58 Mil.

Biohit Oyj's COGS to Revenue for the six months ended in Dec. 2023 was 0.42.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Biohit Oyj's Gross Margin % for the six months ended in Dec. 2023 was 57.54%.


Biohit Oyj COGS-to-Revenue Historical Data

The historical data trend for Biohit Oyj's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohit Oyj COGS-to-Revenue Chart

Biohit Oyj Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.44 0.37 0.35 0.37

Biohit Oyj Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.28 0.44 0.31 0.42

Biohit Oyj COGS-to-Revenue Calculation

Biohit Oyj's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4.792 / 13.076
=0.37

Biohit Oyj's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.792 / 6.576
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohit Oyj  (OHEL:BIOBV) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Biohit Oyj's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2.792 / 6.576
=57.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Biohit Oyj COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biohit Oyj's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohit Oyj (OHEL:BIOBV) Business Description

Traded in Other Exchanges
N/A
Address
Laippatie 1, Helsinki, FIN, 00880
Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies and service laboratory operations.

Biohit Oyj (OHEL:BIOBV) Headlines

No Headlines